JNJ-38877618

JNJ-38877618 (also known as OMO-1 and DO-1) is a potent, highly selective, orally bioavailable small molecule inhibitor of the MET (c-Met) receptor tyrosine kinase. It was initially developed by Johnson & Johnson and later licensed to OCTIMET Oncology. The drug exhibits nanomolar binding affinity for wild-type and mutant forms of MET kinase and has demonstrated preclinical efficacy in models of MET-amplified or mutant cancers. Its mechanism involves inhibition of the MET signaling pathway, which is implicated in tumor growth, survival, migration, and resistance to certain therapies. Clinical studies have shown promising activity in patients with advanced cancers harboring MET mutations or amplifications[2][3][4][5][7][8].

Other names

DO-1DO1DO 1